Literature DB >> 12138172

High level expression of recombinant porcine coagulation factor VIII.

Christopher B Doering1, John F Healey, Ernest T Parker, Rachel T Barrow, Pete Lollar.   

Abstract

Recombinant human factor VIII expression levels, in vitro and in vivo, are significantly lower than levels obtained for other recombinant coagulation proteins. Here we describe the generation, high level expression and characterization of a recombinant B-domain-deleted porcine factor VIII molecule. Recombinant B-domain-deleted porcine factor VIII expression levels are 10- to 14-fold greater than recombinant B-domain-deleted human factor VIII levels by transient and stable expression in multiple cell lines. Peak expression of 140 units x 10(6) cells(-1) x 24 h(-1) was observed from a baby hamster kidney-derived cell line stably expressing recombinant porcine factor VIII. Factor VIII expression was performed in serum-free culture medium and in the absence of exogenous von Willebrand factor, thus greatly simplifying protein purification. Real time reverse transcription-PCR analysis demonstrated that the differences in protein production were not caused by differences in steady-state factor VIII mRNA levels. The identification of sequence(s) in porcine factor VIII responsible for high level expression may lead to a better understanding of the mechanisms that limit factor VIII expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12138172     DOI: 10.1074/jbc.M206959200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.

Authors:  Ernest T Parker; Pete Lollar
Journal:  Biochemistry       Date:  2007-08-04       Impact factor: 3.162

2.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

3.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

4.  Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.

Authors:  P M Zakas; K Vanijcharoenkarn; R C Markovitz; S L Meeks; C B Doering
Journal:  J Thromb Haemost       Date:  2014-11-11       Impact factor: 5.824

5.  Advancements in gene transfer-based therapy for hemophilia A.

Authors:  Christopher B Doering; H Trent Spencer
Journal:  Expert Rev Hematol       Date:  2009-12       Impact factor: 2.929

6.  Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.

Authors:  Denise E Sabatino; Christian Furlan Freguia; Raffaella Toso; Andrey Santos; Elizabeth P Merricks; Haig H Kazazian; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

7.  Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.

Authors:  Xuefeng Wang; Richard Y Fu; Chong Li; Chun-Yu Chen; Jenni Firrman; Barbara A Konkle; Junping Zhang; Lei Li; Weidong Xiao; Mortimer Poncz; Carol H Miao
Journal:  Blood Adv       Date:  2020-11-24

8.  Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.

Authors:  S L Meeks; J F Healey; E T Parker; R T Barrow; P Lollar
Journal:  J Thromb Haemost       Date:  2009-01-24       Impact factor: 5.824

Review 9.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

10.  Helical organization of blood coagulation factor VIII on lipid nanotubes.

Authors:  Jaimy Miller; Daniela Dalm; Alexey Y Koyfman; Kirill Grushin; Svetla Stoilova-McPhie
Journal:  J Vis Exp       Date:  2014-06-03       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.